Viking Therapeutics (NasdaqCM:VKTX) experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 ...
Zacks.com on MSN6d
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyThe deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad multi-year manufacturing agreement with CordenPharma for both the oral ...
Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback